Recipharm partners with Sato to manufacture in Japan

Published: 21-Mar-2017

Local anaesthetic Emla Patch will be produced by the CDMO in Sweden and distributed in Japan

Contract development and manufacturing organisation (CDMO) Recipharm, has entered into a long term agreement with Sato Pharmaceutical for the commercial manufacture and delivery of Emla Patch to Japan.

Tokyo-based OTC company, Sato, will launch the Emla Patch, a local anaesthetic product. Recipharm’s facility in Karlskoga, Sweden, will produce and deliver to Sato.

After a successful launch in Japan, it is expected that the annual volumes of Emla Patch to Sato will be a significant addition to the present production at the Karlskoga facility.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga said: “We first established a business relationship with Sato in 2012 and this new supply agreement extends our partnership further.”

You may also like